A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Status:
Recruiting
Trial end date:
2029-09-15
Target enrollment:
Participant gender:
Summary
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive
disease features will receive salvage radiation therapy and standard androgen deprivation
therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free
survival when enhanced ADT is used compared to standard ADT.